{"disease":{"id":"solid-tumors-or-lymphoma","name":"solid tumors or lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00840047","title":"Methionine PET/CT Studies In Patients With Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":503,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT01897571","title":"Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT04458389","title":"A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":268,"lead_sponsor_name":"Tayu Huaxia Biotech Medical Group Co., Ltd.","has_results":false},{"nct_id":"NCT05460767","title":"Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":260,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT03886831","title":"A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":232,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT05374226","title":"A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":172,"lead_sponsor_name":"Suzhou Kebo Ruijun Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT05607498","title":"First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"EpimAb Biotherapeutics (Suzhou)Co., Ltd.","has_results":false},{"nct_id":"NCT04718675","title":"A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":135,"lead_sponsor_name":"Kronos Bio","has_results":false},{"nct_id":"NCT06615193","title":"A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":111,"lead_sponsor_name":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04094610","title":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Turning Point Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06445517","title":"Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"InSilico Medicine Hong Kong Limited","has_results":false},{"nct_id":"NCT05880043","title":"GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"GI Cell, Inc.","has_results":false},{"nct_id":"NCT02675439","title":"Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"Chinook Therapeutics, Inc. (formerly Aduro)","has_results":false},{"nct_id":"NCT05564806","title":"Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":38,"lead_sponsor_name":"Eucure (Beijing) Biopharma Co., Ltd","has_results":false},{"nct_id":"NCT02214147","title":"Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03458728","title":"Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT06073938","title":"Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT03403725","title":"MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":28,"lead_sponsor_name":"Menarini Group","has_results":true},{"nct_id":"NCT02259010","title":"A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01327612","title":"Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03188328","title":"Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Alfasigma S.p.A.","has_results":false}],"total":21},"guidelines":[],"source":"Drug Landscape verified database"}